Epic Sciences Inc., a San Diego private biotech company that designs and develops diagnostics in order to treat cancer, has appointed Gregory Lucier as chairman of Epic's board of directors.
Lucier was previously chairman and CEO of Life Technologies, which was acquired by Thermo Fisher Scientific. He joins Epic's board of directors to provide expertise as the company commercializes its circulating rare cell analysis platform with special focus on the development of products and services to detect circulating tumor cells (CTCs).
During Lucier's 11-year tenure at Life Technologies, he led the company from a small start-up known as Invitrogen in 2003, directed the acquisition and merger of Invitrogen with Applied Biosystems in 2008 into the renamed Life Technologies. He then transformed the organization by 2013 into a global, world-leading biotechnology firm with 50,000 products, 10,000 employees and nearly $4 billion in sales in more than 180 countries.